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Use of compounded dispersing media for extemporaneous 
pediatric syrups with candesartan cilexetil and valsartan
Available tablets or capsules for adults are often used to 
prepare extemporaneously formulated medicines appro-
priate for children. The most acceptable drug forms in pe-
diatric population are oral liquids and pharmacists use 
commercial dispersing media to compound syrups from an 
active substance or from tablets available on the market. In 
many countries ready-to-use dispersing media are not 
available or refunded, but pharmacists can use other com-
pounded media, providing their compatibility and stability 
are proven. The aim of this study was to formulate and 
evaluate the stability of syrups with candesartan cilexetil (1 
mg mL–1) and valsartan (4 mg mL–1) extemporaneously pre-
pared using commercial tablets (Diovan® and Atacand®). 
The following three different suspending media, which 
could be easily made in a pharmacy, were investigated: 
V1 – with xanthan gum (0.5 %), V2 – the USP/NF vehicle 
for oral solution and V3 – the medium based on a simple 
sucrose syrup. The stability of preparations was studied 
during 35 days of storage in a dark place at controlled 
tempe rature of 25 and 4 °C. During the study, microscopic 
observation was carried out and pH, viscosity, and concen-
tration of candesartan cilexetil and valsartan were ana-
lyzed. Syrups with valsartan prepared with V2 and V3 
media were stable for 3 or 4 weeks when stored at 25 °C, 
while syrups with candesartan were stable for as long as 35 
days. For syrups prepared using V1 medium, the 14-day 
expiry date was not achieved because of microbial deterio-
ration.
Keywords: extemporaneous formulation, pediatric syrups, 
candesartan cilexetil, valsartan, stability
Abbreviations: CAN – candesartan cilexetil; VAL – valsartan; 
V1 – suspending medium with xanthan gum; V2 – suspend-
ing medium prepared according to the US Pharmacopoeia 
»Vehicle for oral solution« (USP/NF 36/31); V3 – suspending 
medium based on a simple sucrose syrup.
MONIKA MUSKO 1,2,*
MALGORZATA SZNITOWSKA3
1 Department of Pharmaceutical 
Technology, Medical University of 
Bialystok, Faculty of Pharmacy 
Bialystok, Poland
2 Department of Clinical Pharmacy 
Medical University of Bialystok Faculty 
of Pharmacy, Bialystok, Poland
3 Department of Pharmaceutical 
Technology, Medical University of 










Accepted July 8, 2014
* Corresponding author: monikam@umb.edu.pl
464
M. Musko and M. Sznitowska: Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil 
and valsartan, Acta Pharm. 64 (2014) 463–474.
 
There is growing concern in clinical practice about the suitability of medicines for 
children – administration of proper doses and formulations. According to the number of 
PIP applications (Pediatric Investigation Plan) approved by EMA (European Medicines 
Agency), cardiovascular diseases rank seventh among the 17 various therapeutic areas re-
garded as most prevalent in the pediatric population (1). Aside from the abnormalities of 
heart rhythms, hypertension is quite common in the pediatric population, since it can de-
velop in childhood. Hypertension in children is developed as a secondary disease, rooted 
in another medical condition (especially in pre-adolescence) or, as in the case of adults, be-
ing the result of such factors as, e.g., overweight or lack of exercise. Accessibility of the pe-
diatric population to appropriate cardiovascular medicines is still low. Although over recent 
years, ever more drugs used in cardiovascular diseases are granted pediatric licenses (e.g., 
captopril, enalapril, amlodipine), one can still encounter medicines used off-label, which are 
registered for adults only or do not have an appropriate pediatric pharmaceutical form. If 
an appropriate pediatric dosage form or a dose is unavailable, medicines for adults have to 
be adjusted by splitting or crushing tablets. An appropriate dose is often obtained when 
extemporaneous powders are prepared by pharmacists.
Liquid extemporaneous pediatric forms are more common in North America, United 
Kingdom, Portugal, Spain, whereas powders are often prepared in Eastern Europe (2, 3). 
Although syrups are a better application form, it is necessary to conduct stability studies 
even for short-time storage and careful selection of the suspending medium is obligatory. 
Stability should be confirmed separately for each combination of brand tablet/capsule and 
suspending medium, since different interactions are possible not only with water but also 
with other additives.
Although candesartan cilexetil (CAN) and valsartan (VAL) belong to the antihyperten-
sive drugs most commonly used in the pediatric population, their liquid dosage forms are 
not available. Both drugs are angiotensin II receptor antagonists. They could be used in 
monotherapy or in the combination with other antihypertensive drugs, as indicated in pre-
scribing information of Atacand® and Diovan® products (4–7) and in the literature (8–11).
Candesartan cilexetil is available in the form of uncoated 4, 8, 16 and 32 mg strength 
tablets and is used in the treatment of adults and children from 1 to 17 years of age. For 
children below 6 years of age, the daily dose range is 0.05 to 0.4 mg kg–1, applied once 
daily or divided into two equal doses (5). The tablets, however, are not suitable for small 
children, who are unable to swallow tablets or capsules. Valsartan (VAL) is available in 
tablets containing 40, 80, 160 or 320 mg of active substance. VAL is registered for the treat-
ment of hypertension in children from 6–18 years of age with a starting dose of 1.3 mg/kg, 
administered once daily. The dose can be increased to a maximum daily dose of 40 mg. 
Although the safety and efficacy of CAN and VAL were confirmed by Schaefer et al. (12, 13) 
in children aged 12 and 6 months, respectively, the use of VAL in children younger than 6 
years is still an off-label practice.
VAL and CAN are rare examples of tablets that can be used for the preparation 
of pediatric oral liquids as »industry-verified preparations«. This term means that oral liq-
uids would be prepared from marketed tablets or capsules employing a method provided 
by the manufacturer in the product leaflet, well-defined and verified, guaranteeing stabil-
ity and dose uniformity of the syrup (14). Astra Zeneca, the manufacturer of tablets with 
CAN (Atacand®), recommends in its drug information leaflets that syrup can be prepared 
by a pharmacist from the tablets using as a suspending liquid a mixture of Ora-Plus® and 
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sugar-free Ora-Sweet SF® (1:1) or a sugar-free Ora-Blend SF®vehicle. The former suspending 
medium is proposed by Novartis, the manufacturer of Diovan® (VAL tablets), for preparing 
a pediatric »industry verified liquid« from these tablets.
Ora® products (Ora-Sweet®, Ora-Sweet SF®, Ora-Plus®, Ora-Blend®, Ora-Blend SF®) are 
aqueous syrups, sweetened and flavored (except for Ora-Plus®). They are used to simplify 
compounding of extemporaneous oral suspensions and syrups. The Ora-Plus® and Ora-
Blend® contain suspending agents (microcrystalline cellulose, carboxymethylcellulose so-
dium, xanthan gum, carrageen) forming colloidal solutions and preventing the powdered 
tablet mass to settle. They are preserved with methylparaben and potassium sorbate and 
phosphate buffer allows maintenance of a slightly acidic pH. Ora-Plus®, as a non-flavored 
vehicle, could be combined with Ora-Sweet® to produce a pleasant taste of the suspension 
(15).
Suspension with Atacand® tablets can be prepared in a CAN concentration within the 
range of 0.1 to 2.0 mg mL–1, but the most commonly recommended concentration is 1 mg 
mL–1. The suspension should be stored in an amber polyethylene bottle at room temperature 
and used within 30 days after the first opening (5). Suspensions at a concentration of 4 mg 
mL–1 VAL are obtained by simply disintegrating the tablets in a vehicle while shaking them 
in the final container. The prepared suspension remains stable for 30 days when stored at 
room temperature or up to 75 days under refrigerated conditions (7).
In some countries, the availability of Ora® suspending media (Perrigo Company plc, 
Ireland) is limited and, moreover, the final cost of the prepared extemporaneous syrups is 
high due to legal regulations in force, which do not allow the refunding of preparations 
made of components not registered for pharmaceutical use (commercial suspending media 
are not registered as such). It is, therefore, necessary to use simple suspend ing vehicles in 
syrups that could be prepared in a pharmacy from components registered for pharmaceuti-
cal use. Such compositions are provided in the literature (16, 17). The USP/NF Pharmaco-
poeia (17) contains formulas for preparing vehicles for oral solutions or suspensions as well 
as other flavoring syrups (e.g., Sugar-Free Suspension Structured Vehicle, Vehicle for Oral 
Solution, Vehicle for Oral Suspension, and Raspberry Syrup, Cherry Syrup, Chocolate Syr-
up or Orange Syrup).
The aim of this study was to develop and assess the stability of extemporaneous syrups 
with CAN or VAL prepared with simple suspending media compounded in a pharmacy. 
The developed syrups, prepared in pediatric doses from commercially available tablets with 
three different media, were analyzed and the expiry date was proposed.
EXPERIMENTAL
Chemicals and reagents
Tablets for syrup preparation were obtained from a local pharmacy: Atacand® (Astra 
Zeneca AB, Sweden), containing 16 mg of candesartan cilexetil and Diovan® (Novartis, 
Germany) with 160 mg of valsartan. Atacand® tablets are uncoated and contain the follow-
ing excipients: calcium salt of carboxymethylcellulose, hydroxypropylcellulose, lactose 
monohydrate, magnesium stearate, corn starch, polyethylene glycol 8000, iron oxides. Dio-
van® coated tablet (taste masking coating) contains a microcrystalline cellulose, polyvinyl-
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pyrrolidone, colloidal silica, magnesium stearate, hypromellose, titanium dioxide, poly- 
ethylene glycol 8000 and iron oxides. Reagents used in the analysis were of HPLC grade: 
acetonitrile (POCH, Poland), methanol (J. T. Baker, Netherlands), ortho-phosphoric acid 
(Fluka, Switzerland). Candesartan cilexetil and valsartan, used as standards, were kindly 
donated by Polpharma (Poland). Other chemical substances and solvents necessary to pre-
pare syrup vehicles were of pharmacopoeial quality. Xantural® 180 (xanthan gum) was 
purchased from CP Kelco (Poland).
Vehicles and pediatric syrup formulation
Syrups with CAN and VAL were prepared in pediatric doses using three syrup vehi-
cles, whose composition is given in Table I. Vehicle V1 was a suspending medium based on 
xanthan gum (0.5 %), V2 was a »vehicle for oral solution« prepared according to US Phar-
macopoeia (17) and V3 was prepared from the pharmacopoeial sucrose simple syrup (17) 
with added sorbitol and glycerol. No preservatives were added to vehicleV3, while V1 and 
V2 were preserved with methylparaben and V2, additionally, with potassium sorbate. V2 
was a buffered medium.
Syrups containing CAN in 1 mg mL–1 concentration or VAL in 4 mg mL–1 concentration 
were prepared by suspending powdered tablets in the prepared media. Tablets were 
crushed and powdered in a mortar, then a portion of vehicle was added to form a smooth 
paste. Additional vehicle was added in portions. The suspension was transferred into a 
glass-graduated cylinder and the rest of the vehicle was used to rinse the mortar and to 
make a proper volume. Each of the syrups was prepared in one batch and placed in amber 
glass bottles. The syrups were stored at controlled temperatures of 25 and 4 °C and pro-
tected from light. In each syrup, visual (intensity of sedimentation) and microscopic obser-
vation was performed and the pH, viscosity, and concentration of CAN and VAL were 
measured periodically, every 7 days for up to 35 days.
Table I. Characteristics of syrup suspending media used in the study: composition, pH and viscosity





Xanthan gum (Xantural® 180)   0.50 – –
Sucrose – 80.00 54.0
Sorbitol 10.00   5.00   4.0
Glycerol –   5.00   5.0
Xylitol   4.00 – –
Sodium phosphate dibasic –   0.12 –
Citric acid –   0.20 –
Methylparaben   0.20   0.10 –
Potassium sorbate –   0.10 –
Water to 100.00 to 100.00 to 100.00
pH   5.53   4.78     6.69
Viscosity (mPa s) 197.000 117.000 67.0
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Microscopic analysis
Samples of each syrup were observed by means of an optical microscope (Motic BA 
400, Moticam camera 2.0 MP, Germany) using total magnification of 100 and 400. Maximum 
particle size (length parameter) was measured for particles present in at least three different 
areas of observation.
Intensity of sedimentation
Each syrup was placed in a glass scale tube, achieving a 10 cm height of the liquid. In 
the course of visual observation, the character and volume of the forming sediment as well 
as the presence of floating particles were taken into consideration. The ease to re-disperse 
the precipitated particles was evaluated visually after manual shaking of the bottles with 
syrups where sedimentation occurred.
Viscosity measurement
Viscosity of all syrups was measured using a rotational viscometer (Viscotester E 
Plus – Thermo Haake, Thermo Electron Corporation, Germany). Resistance of a tested 
sample to torque was evaluated. Rotation speed was chosen empirically and was set at 
200 rpm.
Analysis of drug concentration
Determination of CAN and VAL was performed by means of the high-performance 
liquid chromatography (HPLC) analysis. Previously described methods for determination 
of VAL (18–20) and CAN (21, 22) in dosage forms were employed, with minor modifications. 
It was confirmed that the method was specific and accurate in the presence of syrup com-
ponents. Isocratic separation was carried out on an Eclipse XDB – C18 (particle size 5 µm, 
4.6 × 150 mm) using an Agilent HPLC system (Agilent Technologies 1260 Infinity, Germany). 
The mobile phase for CAN analysis was a mixture of phosphate buffer pH 3.0 (0.05 mol L–1), 
methanol and acetonitrile (30:20:50; V/V) while for VAL a mixture of phosphate buffer pH 
2.7 (0.065 mol L–1) with acetonitrile (55:45; V/V) was used. The flow rate was 1.0 mL min–1. 
The liquid chromatograph was equipped with a UV detector set at 215 nm both for CAN 
and VAL. The injected volume for each sample was 20 µL. Retention times for CAN and 
VAL were about 13 and 5 min, respectively. The analysis was performed at ambient tem-
perature.
Samples for active substance analysis were withdrawn from each syrup and analyzed 
in triplicate. The syrups were shaken by hand, approximately for 30 seconds, and the volume 
of 1.0 mL was withdrawn and diluted to 10.0 mL with methanol. The solution was thor-
oughly shaken by hand for 1 min and this was followed by centrifugation (15 min, 4000 
rpm). The supernatant (1.0 mL) was diluted (to 10.0 mL) with a mobile phase to obtain solu-
tions at concentrations of approximately: 10 µg mL–1 for CAN and 40 µg mL–1 for VAL, 
which were injected into the HPLC column (20 µL).
Examples of chromatograms are presented in Figs. 1 and 2. CAN and VAL concentra-
tions in the tested samples were calculated from standard curves obtained from the analy-
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sis of standard solutions within the concentration range of 1–20 and 10–80 µg mL–1, for CAN 
and VAL respectively. Linearity of the curve was confirmed by the correlation coefficient, 
which was greater than 0.999. Interday precision for CAN and VAL was 4.52 and 1.15 %, 
respectively (relative standard deviation).
V2 – = 0t V2 – = 35 dayst
Time (min)













0 2 4 6 8 10 12
V3 – = 0t V3 – = 35 dayst
Time (min)




















































V2 – = 0t V2 – = 35 dayst
Time (min)








0 1 2 3 4 5 6
V3 – = 0t V3 – = 35 dayst
Time (min)














































Fig. 1. Chromatograms of candesartan cilexetil syrups prepared with V2 and V3 media – analysis per-
formed after preparation (t = 0) and after 35 days of storage at 25 °C.
Fig. 2. Chromatograms of valsartan syrups prepared with V2 and V3 media – analysis performed 
after preparation (t = 0) and after 35 days of storage at 25 °C.
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All compounded CAN syrups have the same pink, milky color that comes from the 
tablet dye. No changes in color, odor, taste or smell were observed in syrups prepared with 
V2 and V3, stored at both temperatures. On the other hand, in syrups prepared with V1, an 
unpleasant smell and taste were detectable after 14 days of storage at both temperatures, 
which could indicate a microbial and/or fungal growth. Possible reason for this observation 
could be a decrease in the efficiency of the preservative used in the V1 medium (methyl-
paraben) in the presence of excipients coming from the tablet, especially if some of them are 
insoluble and the preservative may be adsorbed on the suspended particles. Thus, methyl-
paraben (0.2 %), the preservative used in V1, might be insufficient to ensure microbial stabil-
ity of the proposed preparation. An additional preservative, like potassium sorbate used in 
Ora® products, could be required.
After 7 days of storage, sedimentation of the suspended particles was observed in 
syrups prepared with V2 and V3 vehicles at both 25 and 4 °C. At the same time, the appear-
ance of a characteristic, floating, pink layer on the surface of syrups was noted, which re-
mained up to the end of the study. Complete separation of solid particles and the vehicle 
was observed after 4 weeks only in syrups prepared with V2. In spite of this, homogeneity 
of each syrup was easily achieved after short manual shaking. In contrast to V2 and V3 
vehicles, sedimentation did not occur in syrups prepared with V1, since it was prevented 
by higher viscosity of the preparations (see Fig. 3A).
CAN is practically insoluble in water (< 0.01 %). In the prepared syrups, CAN is pres-
ent in solid state together with insoluble excipients from the tablet (corn starch, magnesium 
stearate, iron oxides). A slowly progressing dissolution of tablet excipients (i.e., calcium salt 
of carboxymethylcellulose, hydroxypropylcellulose, lactose monohydrate) occurred and 
was observed as an increasing haziness of the syrups. Microscopic analysis has shown that 
the range of particle size did not change significantly; it did not exceed 30 µm in any vehicle. 
No aggregation of particles was observed either.
Fig. 3. Changes in viscosity of syrups with: a) candesartan cilexetil and b) valsartan prepared with 
V1, V2 and V3 media, stored for 35 days at 25 and 4 °C.
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The initial pH value in the prepared media was 5.53; 4.78 and 6.69, for V1, V2 and V3, 
respectively. After adding the powdered tablets to the medium, the pH changed only slight-
ly and the values of 5.81, 4.65 and 6.12 were measured for syrups prepared with V1, V2 and 
V3 media, respectively. These changes were considered as being non-relevant for influenc-
ing CAN stability.
The pH of the syrups prepared with V1 or V2 did not change significantly over the 
stability study period at either temperature. The above mentioned organoleptic changes in 
the V1 syrup did not influence pH either. A small decrease in pH was observed at both stor-
age temperatures in the syrup prepared with the unbuffered V3 medium (from the initial 
value 6.12 to around 5.66 on day 35 of the study).
Viscosity of the tested vehicles is shown in Table I. The dispersing mediumV1 is most 
viscous, as it contains a polymer xanthan gum. The added powdered CAN tablets (0.81 % 
m/m) practically did not influence the viscosity of vehicles, as can be seen in Fig. 3a in com-
parison with the data in Table I. Rheological changes in all formulations were noted during 
the study period; however, the slightest viscosity difference was observed in the syrup 
prepared with V3 (Fig. 3a). The biggest drop in viscosity, irrespective of storage tempera-
ture, occurred during 14 days in the formulation prepared with V1 (from 207 mPa s to 86 
mPa s), which was followed by a further increase to 142 mPa s and stabilization after 21 
days. As mentioned above, changes in the viscosity of V1 vehicle could be related to micro-
bial contamination. In V2 syrups, viscosity increased slightly after 7 days, but it was lower 
than initially after 21 days. The first observation may be explained by the slow dissolution 
of the tablet mass components (colloidal substances), as already mentioned above; how-
ever, further decrease in viscosity may be related to some other structural changes of the 
solid phase, although this has not been studied in detail. Noted changes in viscosity did not 
cause any problems during the administration of syrups.
To establish the expiry date for the prepared extemporaneous syrups, HPLC determi-
nation of CAN was required. The results are shown in Fig. 4a, as the percentage of CAN 
compared to the initial concentration of 1 mg mL–1. In all syrups, no significant changes in 
the active substance concentration were noted during the 35 days of observation, and the 
range of 95–105 % of the initial concentration was not exceeded. Only in V3, the content of 
CAN was beyond this limit after 7 and 28 days; however, the analysis performed at these 
time points did not confirm the change in the drug content. No peaks from degradation 
products, namely candesartan and desethyl candesartan cilexetil (under the chromatogra-
phy conditions expected at the retention times of 1.9 min and 5.2 min), were observed in 
the chromatograms (Fig. 1).
As already mentioned in the introductory section, the suspensions prepared with Ata-
cand® tablets and Ora® syrups are stable for 30 days at room temperature. Our results 
demonstrate that the same stability can be achieved with the suspending media compound-
ed in a pharmacy, namely pharmacopoeial medium V2 and simple medium V3.
Valsartan
All syrups prepared with VAL were cream-colored and with visible orange particles 
from the tablet’s coat. The sweet smell and taste were unchanged in V2 and V3 syrups dur-
ing storage for 35 days at 25 and 4 °C. In the formulation prepared with V1, however, the 
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same unpleasant smell as noted in syrup with CAN appeared after 2 weeks of storage. Due 
to high sugar concentration and the resulting high osmotic pressure, the unpreserved 
vehicle V3 did not cause any problems with microbiological stability as observed in V1 
medium.
In both VAL and CAN syrups, the proportion of powdered tablet mass was similar, 
i.e., 0.8 % (m/m). Sedimentation processes in VAL syrups were generally similar to those 
observed in CAN syrups: with phase separation, sedimentation and also some floating 
solids in V2 and V3 vehicles and with no sedimentation in V1 vehicle. In the less viscous V3 
medium, the volume of the sediment formed was larger than in V2 medium. The sediments 
in syrups were downy and easily re-suspendable after short manual shaking. In all VAL 
syrups, a milky, moody liquid above the sediment was observed over the whole period, as 
opposed to CAN syrups.
Despite the different pH values measured in the suspending vehicles (Table I), the pH 
values of the syrups prepared with VAL were similar, ranging from 4.27 (syrup with V1) 
to 4.68–4.71, indicating that tablet mass creates a buffered system. The pH value in all VAL 
syrups was not changed significantly during the study period at either temperature. Deg-
radation of VAL in strongly acidic solutions is much faster than under alkaline conditions 
(23, 24), but less acidic solutions do not cause degradation, as can be concluded from the 
good stability of VAL in Ora® syrups (pH 4–5) (7, 25, 26).
When VAL was added to the studied media as a drug substance, it did not dissolve 
completely even in a concentration of 1 g L–1. This is consistent with the information re-
ported in the literature that VAL solubility in water at 25 °C was 0.18 g L–1 and increased to 
16.8 g L–1 only in a phosphate buffer at pH 8.0 (27). This points to the conclusion that in all 
prepared syrups, at acidic pH, VAL is mostly present in an insoluble form. Some other in-
soluble excipients derived from the tablet (microcrystalline cellulose, crospovidone, col-
loidal silica) remain also suspended in the syrup.
Microscopic analysis has shown that, like in CAN syrups, the range of the suspended 
particle size did not change significantly during storage, not exceeding 30 µm in any 
vehicle .
Fig. 4. Stability (% of initial concentration) of: a) candesartan cilexetil and b) valsartan in syrups pre-
pared with V1, V2 and V3 vehicles, stored at 25 and 4 °C for 35 days.
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As demonstrated in Fig. 3, the viscosity of all prepared syrups was the same as in those 
with CAN, which indicates that the suspended tablets did not significantly affect the rheol-
ogy of vehicles. As in the case with CAN, the viscosity of V2 and V3 syrups with VAL was 
practically unchanged during storage, although V2 syrups demonstrated a slight decrease 
in viscosity after 7 days, while the viscosity was increased in CAN syrups at that time point. 
Similarly to CAN formulations, a significant drop in viscosity occurred in the V1 syrup 
after 2 weeks of storage. However, the values were high again after another week; thus, the 
behavior of this vehicle in the presence of VAL was different from CAN. A temporary de-
crease in viscosity of the V1 formulation may probably be explained by two independent 
processes – microbial growth and the interaction of xanthan gum with tablet excipients; this, 
however, would require further studies.
The method of preparing syrups from VAL tablets, as described and recommended by 
the manufacturer, relies on tablet dispersion during intensive manual agitation with a mix-
ture of commercially available vehicles (Ora® products), while the suspension proves to be 
stable for 30 days at 25 °C and 75 days at 4 °C (25, 26). In all the proposed vehicles, Diovan® 
tablets disintegrated during stirring, so the same method of preparation, as that recom-
mended for Ora® medium, can be proposed.
Analysis of VAL concentration has shown that the most stable syrups were prepared 
with vehicle V1. In those formulations, the percentage of the initial concentration was 100–
103.7 % throughout the whole study period (Fig. 4B). In contrast, significant changes were 
observed in syrups prepared with V2 and V3. A higher than 10 % decrease of the initial drug 
content was observed in syrups prepared with V2 and V3 after 4 and 3 weeks of storage at 
25 °C, respectively. At 4 °C, the same result was observed one week later. This means that 
the recommended expiry date for VAL syrups stored at 25 °C should be maximally 3 weeks 
if prepared with V2, and 2 weeks if V3 is used, because within such periods the content of 
the active substance was within 90–110 % of the declared content. The 4-week storage for 
the syrup prepared with V2 can be proposed under storage conditions of 4 °C. The stability 
data of VAL in the mixture of Ora-Sweet® and Ora-Plus® (1:1) show that the syrup is stable 
for 30 days when stored at 30 °C and stable for 75 days when stored at 2–8 °C (7). Thus, our 
results demonstrate that the proposed, compounded suspending media do not offer long 
chemical stability. However, it must be noted that long-term storage of extemporaneous, 
water-containing pharmaceutical preparations should be avoided and the storage time 
limit should not exceed 14 days, as recommended in the USP (17). This is especially impor-
tant if preparations are prepared from tablets, since they are not intended as stock prepara-
tions.
CONCLUSIONS
The compounded suspending media allow the preparation of pediatric extemporane-
ous syrups from tablets with VAL or CAN. When V2 or V3 media were used, the stability 
of syrups with CAN was proven to be 35 days. VAL was less stable and due to the loss of 
drug content below 90 % of the initial dose, only 3 or 2 week-long stability was achieved for 
V2 and V3 media, respectively, at 25 °C, which was a shorter time than the time reported 
for Ora® commercial suspending media. It has to be taken into account, however, that stor-
age time should be kept as short as possible for extemporaneous syrups, not only due to 
microbial stability but also due to unexpected incompatibilities, which may occur in the 
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aqueous environment between the tablet’s excipients and drug substance or ingredients of 
the syrup medium. Thus, as recommended by the USP, a 14-day expiry date is most ap-
propriate for an aqueous compounded pharmaceutical preparation and can be achieved in 
V1 or V2 media for both VAL and CAN.
The suspending medium V1 is problematic due to unsatisfactory microbial stability, 
followed by an unpleasant odor appearing in syrups with VAL or CAN after 14 days of 
storage at both 25 and 4 °C. However, satisfactory physical and chemical properties of the 
V1 syrups, such as palatability, homogeneity maintenance and proven drug assay stability, 
make this medium a good syrup vehicle. What remains to be considered in the follow-up 
studies is the change of the preservative substance in order to extend and confirm micro-
biological stability.
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